This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
NCT03100864
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class
Conditions
Colitis, Ulcerative
Interventions
DRUG:
Spesolimab
Sponsor
Boehringer Ingelheim